NuLiv Science's JointIQ® Ingredient: A Breakthrough in Joint Health
NuLiv Science, a renowned company specializing in plant-based nutraceutical ingredients, has made a significant stride in the field of joint health. Their latest product, JointIQ®, derived from
Astragalus membranaceus saponins, has been a subject of interest following the release of the first human clinical study demonstrating its benefits for improving joint health and cartilage markers in active adults.
Background of the Study
The study, published in the academic journal
Nutrients, aimed to evaluate the effects of JointIQ® on joint comfort, mobility, and cartilage health. Conducted with a randomized, double-blind, placebo-controlled design, the research involved
50 active adults who reported experiencing knee discomfort but had no diagnosed joint ailments. Participants took either one capsule of JointIQ® or a placebo daily over a span of
12 weeks.
Researchers tracked various metrics at the beginning of the trial and again at the 12-week mark to observe any changes in knee function and subjective experiences using tools like the KOOS (Knee injury and Osteoarthritis Outcome Score) questionnaire. They also performed physical tests, including a single-leg step-down assessment and measures of knee movement range.
Key Findings
The results were telling. Those supplemented with JointIQ® exhibited notable improvements in knee-related quality of life, with the study revealing that their knee extension mobility had significantly progressed compared to the placebo group. Specifically, the participants taking JointIQ® recorded an approximately
20% increase in step-down performance and a
33% reduction in recovery time post-test. Additionally, improvements were seen across all areas of the knee questionnaire with the most pronounced benefits in sports performance and overall quality of life.
Interestingly, the initial analysis of blood markers associated with inflammation and cartilage health demonstrated a positive trend, with inflammation markers such as IL-8 and MMP-13 showing reductions, while a marker engaging in cartilage production, PIINP, rose. Though these biomarker results are preliminary, they align with findings from previous laboratory experiments investigating JointIQ®'s behavior in cartilage cells.
Insights from NuLiv Science's Leadership
Richard Wang, CEO of NuLiv Science, expressed excitement about the study's outcomes, stating, "This first human study on JointIQ® represents a milestone for us in promoting joint health. Our commitment to this ingredient spans
25 years in combining traditional practices and contemporary cellular research. Now, the human data significantly supports our past studies, providing a comprehensive backing for our product development."
Conclusion
As the trend towards plant-based health supplements continues to gain momentum, the promising results from the JointIQ® trial underscore NuLiv Science's dedication to innovation in dietary health solutions. For individuals seeking to enhance their joint health and overall quality of life, JointIQ® appears to be a noteworthy addition to their wellness regimen.
For further inquiries or details about the JointIQ® ingredient and its proven advantages, visit
NuLiv Science.
NuLiv Science's rich legacy as a
Certified B Corp and its commitment to harnessing the power of traditional medicine confirms its position at the forefront of nutraceutical advancement. Founded in 1997, NuLiv Science continues to collaborate with academic institutions, deriving scientific insights to offer cutting-edge ingredients that elevate health and wellness standards.